Laboratory Testing Takes Center Stage in Targeted Therapy Amid Rising Antibiotic Resistance

According to the World Health Organization’s (WHO) Global Antimicrobial Resistance Surveillance Report, roughly one in six common bacterial infections exhibits antibiotic resistance, bringing rational antibiotic use into sharp focus during World AMR Awareness Week (November 18–24). Beckman Coulter Diagnostics Turkey General Manager Berna Ünses emphasized that diagnostic tests enabling early differentiation between bacterial and viral infections, alongside antimicrobial susceptibility solutions, play a critical role in guiding accurate treatment decisions.

Unnecessary or inappropriate use of antibiotics—which are ineffective against viral infections—accelerates bacterial resistance and complicates treatment. Drawing on data from over 100 countries, the WHO report indicates that resistance rates increased in more than 40% of pathogen-antibiotic combinations, with an average annual rise of 5% to 15%. Meanwhile, according to the Turkish Ministry of Health’s National Action Plan on Combating Antimicrobial Resistance (2026–2030), daily antibiotic consumption in Turkey rose from 34.2 doses per 1,000 inhabitants in 2022 to 41.1 doses in 2023, remaining above the OECD average.

Berna Ünses: “Accurate Test Results Help Physicians Select the Most Appropriate Therapy”

Commenting on the occasion of World AMR Awareness Week, Berna Ünses, General Manager of Beckman Coulter Diagnostics Turkey, stated:

“Antibiotic resistance carries the risk that infections we can treat today may become far more difficult to treat in the future. Therefore, the proper use of antibiotics is an issue that concerns all of our health. Laboratories and laboratory tests play a vital role in this fight. While an accurate test result helps physicians establish the right diagnosis and choose the most appropriate therapy, the resulting data is also used to monitor the spread of resistant bacteria. Distinguishing bacterial and viral infections as early and accurately as possible can contribute to more rational antibiotic use. At Beckman Coulter Diagnostics, we support laboratories in these efforts with the technologies we develop.”

The Role of Laboratory Technologies from Diagnosis to Treatment

Throughout the diagnostic workflow supporting antimicrobial stewardship, targeted laboratory technologies provide actionable clinical insights:

  • Early Differentiation of Bacterial and Viral Infections: Rapid diagnostic tests that distinguish between viral and bacterial infections—which often present with overlapping symptoms—provide physicians with objective data to evaluate whether antibiotic therapy is truly warranted.

  • Bacterial Identification and Antimicrobial Susceptibility Testing (AST): Identification and susceptibility solutions pinpoint the causative pathogen and determine which antibiotics it is sensitive or resistant to, measuring the minimum inhibitory concentration required to halt bacterial growth and guide targeted therapy.

  • Digital Surveillance and Data Management: Beckman Coulter Diagnostics’ laboratory software streamlines the recording of test results and tracking of antimicrobial resistance trends, supporting the entire workflow from diagnosis to treatment.

Related News